Skip to content

Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis

Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis. Randomized, Blinded, Placebo-controlled Clinical Trial.

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02280096
Enrollment
24
Registered
2014-10-31
Start date
2014-10-31
Completion date
2017-02-28
Last updated
2019-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Keywords

Cognitive function, Multiple sclerosis, 4-aminopyridine, Fatigue

Brief summary

Twenty four relapsing-remitting multiple sclerosis (RRMS) patients over the age of 18, with similar degree of disability, and with an evolution of at last 6 months, who are in first-line immunomodulatory therapy and have a stable disease (no more than one outbreak per year) will be included in the present study. Patients will be administered a neuropsychological test battery selected for this study and divided into two sessions of one and a half-hour each. Emotional state will be assessed with the Beck Depression Inventory in a different session. Cognitive impairment is defined as the alteration of two or more neuropsychological tests. Patients will be divided randomly into two groups where one will receive placebo and the other one 4-Aminopyridine (4-AP) for a period of 22 weeks in increasing doses.

Detailed description

Consecutive patients with stable multiple sclerosis are being recruited from the neurological services of Social Security Mexican Institute (IMSS) at the National Medical Center (CMN) Siglo XXI Specialties Hospital over the period of 1 year. Of those meeting inclusion criteria, 24 will be selected for the study. After signing an informed consent, they will be randomized into 12 for the intervention arm and 12 for the placebo arm. All patients will receive capsules for daily consumption according to their assignment, with no visible difference between capsules. Dosage will be 6.5-7.5 mg/kg to a limit of 50 mg. These capsules will be taken for a period of 22 weeks. A battery of neuropsychological tests will be administered at baseline, after 22 weeks, and after an additional 22 weeks of follow-up to assess cognitive performance and motor function. Emotional state will be assessed with the Beck Depression Inventory at each of the three afore mentioned points. After the follow-up period, all test results will be analyzed and compared to determine the efficacy and safety of 4-aminopyridine on the cognitive performance and motor function of patients. Mann-Whitney U will be used for statistical analysis.

Interventions

Each patient will take two capsules every 8 hours after meals, for a total of 6 capsules/day. The 4-aminopyridine dosage will increase 10 mg/4 weeks by substitution of placebo instead of 4-aminopyridine capsules; such that patients will receive from 40 to 60 mg. distribute in 6capsules/day throughout the study.

DRUGPlacebo

The placebo arm will include Microcrystalline Cellulose placebo

Sponsors

Coordinación de Investigación en Salud, Mexico
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

Patients with multiple sclerosis (MS) are eligible for the study if they meet the following criteria: 1. Relapsing recurrent MS with an evolution of at last 6 months before the study began. 2. Both males and females, aged 20 - 65 years 3. Neurologic Expanded Disability Status Scale (EDSS) 3 - 7 4. Who are in first-line immunomodulatory therapy and have a stable disease 5. No more than one outbreak per year. 6. The absence of antiepileptic antecedent and electroencephalogram without epileptic activity. 7. For females: postmenopausal or surgically sterile, or using an acceptable method of birth control

Exclusion criteria

1. History of cardiovascular disease (syncope, arrhythmia, or myocardial infarction within the last two years), systolic blood pressure greater than 150 or less than 70 mm Hg, diastolic blood pressure greater than 110 or less than 50 mm Hg, or heart rate greater than 110 or less than 50 beats/minute; impaired hepatic function (total hepatic enzyme or bilirubin levels greater than 2 times the upper limits of normal) or impaired renal function (creatinine level greater than 2 times the upper limits of normal) less than 6 months before the study 2. Known allergy to pyridine-containing drugs 3. Neurologic, degenerative, or psychiatric disorders that would impair the patient's ability to complete the protocol 4. Any illness or abnormality that would jeopardize patient safety or interfere with the conduct of the study 5. History of substance abuse 6. Inability to discontinue excluded concomitant drug therapy

Design outcomes

Primary

MeasureTime frameDescription
Tower Of London (TOL). Execution Time and Problem-solving Time25-30 minutesMeasures higher-order problem-solving ability. The information it provides is not only useful when assessing frontal lobe damage, but also when evaluating attention disorders and executive functioning difficulties. The administrator arranges red, green, and blue beads on a peg board to match the configuration in the diagram. The patient is asked to replicate the configuration on a second peg board. Scores are calculated for Total Execution Time (since the patient performs the first move until he ends the test), Total Problem-Solving Time (the sum of planning and execution times). Total execution time higher scores indicate a worse outcome (min= 0-78, max=564+ seconds), Total problem-solving time higher scores indicate a worse outcome (min= 0-56, max=500+ seconds).
Five Digit Test (FDT). Processing Speed8-10 minProcessing speed information (which includes reading, count, and alternation speed). Cards with a different number of stimuli are shown to the patient, who has to read, count, and respond to a change of instructions (alternation). Reading speed (min 12, max 31+ seconds), counting speed (min 14, max 28+ seconds), and alternation speed (min 26, max 56+ seconds) are recorded. Less speed corresponds to a better outcome.
Wisconsin Card Sorting Test (WCST)10-15 minutesIs used primarily to assess perseveration and abstract thinking, allows the clinician to assess the following 'frontal' lobe functions: strategic planning, organised searching, utilising environmental feedback to shift cognitive sets, directing behaviour toward achieving a goal. WCST measures abstract reasoning and ability to alter problem solving strategies. Patients are given 128 response cards and 4 stimulus cards and asked to match each stimulus card to 1 pile of response cards. The patient is not told how to match the cards, only right or wrong to each placement. The examiner may change matching rules during the test. Perseveration errors occur when subject repeats the same error no matter how many times they are told the placement is wrong. Higher scores indicate a worse cognitive performance (min=0-3, max=58-126)
Color Trails Test (CTT)5-8 minutesMeasure sustained attention. The CTT uses numbered coloured circles and universal sign language symbols. The circles are printed with vivid pink or yellow backgrounds that are perceptible to colourblind individuals. For the Colour Trails 1 trial, the respondent uses a pencil to rapidly connect circles numbered 1 through 25 in sequence. Less time indicates better performance (min=10, max= 240).
Tower Of London (TOL). Total Moves and Total Correct Moves25-30 minutesMeasures higher order problem-solving ability. The information it provides is not only useful when assessing frontal lobe damage, but also when evaluating attention disorders and executive functioning difficulties. The administrator arranges red, green, and blue beads on a peg board to match the configuration in the diagram. The patient is asked to replicate the configuration on a second peg board. Scores are calculated for Total Correct Moves and Total Moves. Total moves: higher scores indicate a worse cognitive performance (min= 0, max=58+); Total correct higher scores indicate a better cognitive performance (min=0, max=10).
The Brief Repeatable Battery of Rao10-15 minutesNeuropsychological tests to assess: verbal fluency. Participants have to say as many words as possible from a category in a given time 60 Sec (F, A, S) Max score 72 and min score 19 words. Higher scores indicate a better cognitive performance.
Integrated Program of Neuropsychological Exploration Test Barcelona7-10 minIntegrated Program of Neuropsychological Exploration Test Barcelona: Digit Span Forward (DSF), (attention spam and improved scoring metrics significantly enhance the precision of DSF assessments of short-term verbal memory). Digit sequences are presented beginning with a length of two digits and two trials are presented at each increasing list length. Max score 8 and min score 0 digits. Higher scores indicate a better cognitive performance.
Rey-Osterrieth Complex Figure Test (ROCF)10-15 minutesThe purpose of this test is to assess visual-spatial constructional ability and visual memory. The time required to copy the drawing is recorded. Less time indicates a better performance and more time indicates a worse outcome (min score 60 and max score 300 seconds).

Secondary

MeasureTime frameDescription
Fatigue10 minutesThe Fatigue Severity Scale (FSS) is one of the most frequently used inventories for measuring fatigue in people with chronic illnesses. The FSS questionnaire is comprised of nine statements inquiring about the examinee's sleep habits over the preceding week. Ratings are on a 7-point Likert scale, where higher scores indicate how strongly the patient agrees with the nine statements.Scale. Scoring using a bimodal response system or a Likert score with weights assigned to each response choice. Likert or bimodal rating scales with 4 response options. For the Likert Scale: better than usual= 0, no more than usual= 1, worse than usual= 2, much worse than usual= 3. For the bimodal scale: better than usual= 0, no more than usual= 0, worse than usual= 1, much worse than usual= 1. Sum all items for a total score. Score range. Range is 0 -11 for bimodal response format. Interpretation of scores. Higher score indicates more fatigue. Self report scale
Walk5-10 minutesTimed 25 Foot Walk Test (T25-FW). The T25-FW is a quantitative mobility and leg function performance test based on a timed 25-walk. The patient is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time is calculated from the initiation of the instruction to start and ends when the patient has reached the 25-foot mark. The task is immediately administered again by having the patient walk back the same distance. Patients may use assistive devices when doing this task. TIME LIMIT PER TRIAL (2) 3 minutes (180 seconds) per trial.
Number of Participants With Abnormal Studies22 weeksSafety surveillance will be done every two weeks from the beginning of the study, intentionally searching for adverse events (AE). EEG (Diffuse or focal cerebral dysfunction through demonstration of background slowing or presence of epileptiform activity assessed by a neurophysiologist) and laboratory tests (Presence of values higher of the normal value established by local laboratory and related to the administration of treatments), blood and urine samples: creatinine, blood urea nitrogen, total cholesterol, triglycerides, total direct, and indirect bilirubin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, creatinine kinase, lactic acid dehydrogenase, amylase and lipase. A complete blood cell count with differentials and a routine urinalysis and urine culture also obtained at each visit, will be done before the patients take 40, 50 and 60 mg/day. The number of participants with abnormal studies were reported.
Improved Physical Capacity15-20 minutesThe Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time. It is widely used in clinical trials and in the assessment of people with MS. The EDSS scale ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability. Scoring is based on an examination by a neurologist. The first levels 1.0 to 4.5 refers to people with a high degree of ambulatory ability and the subsequent levels 5.0 to 9.5 refers to the loss of ambulatory ability. It also provides eight subscale measurements called Functional System (FS) scores. The levels of function within each category refer to the eight FS affected by MS: The FS are scored on a scale of 0 (low level of problems) to 5 (high level of problems) to best reflect the level of disability observed clinically.

Countries

Mexico

Participant flow

Recruitment details

Twenty-four patients were recruited, of whom 21 completed the study

Pre-assignment details

Three patients were excluded: one because of lack of adherence to the treatment; another presented an anxiety crisis and third one due to pregnancy. In the end, 11 patients were included in the treatment group and 10 in the placebo (control) group.

Participants by arm

ArmCount
4-aminopyridine Treatment (20 Weeks)
4-aminopyridine is given as gelatin capsules containing 4-aminopyridine 10 mg and microcrystalline cellulose as the excipient. Each patient will take two capsules every 8 hours after meals, for a total of 6 capsules/day. The 4-aminopyridine dosage will increase 10 mg/4 weeks by substitution of placebo instead of 4-aminopyridine capsules; such that patients will receive from 40 to 60 mg. distribute in 6capsules/day throughout the study.
11
Placebo (20 Weeks)
Patients randomized to the placebo sequence will receive placebo for 20 weeks after the run-in period. They will be blinded to the fact that they are taking placebo, and capsules will be identical in appearance to the intervention capsules. Placebo: The placebo arm will include Microcrystalline Cellulose placebo
10
Total21

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyFunctional neurological disorder10
Overall StudyLack of attachment01
Overall StudyPregnancy10

Baseline characteristics

Characteristic4-aminopyridine Treatment (20 Weeks)Placebo (20 Weeks)Total
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
11 Participants10 Participants21 Participants
Age, Continuous39.5 years
STANDARD_DEVIATION 8
34.3 years
STANDARD_DEVIATION 9.8
36.9 years
STANDARD_DEVIATION 8.9
Disease duration8.55 years9.4 years8.97 years
Education15.9 years16.9 years16.4 years
Glatiramer acetate1 Participants2 Participants3 Participants
Interferon beta 1a1 Participants2 Participants3 Participants
Interferon beta 1a subcutaneous3 Participants2 Participants5 Participants
Interferon beta 1b6 Participants4 Participants10 Participants
Mini Mental State Examination (MMSE)27.1 units on a scale
STANDARD_DEVIATION 1.4
27 units on a scale
STANDARD_DEVIATION 1.6
27.05 units on a scale
STANDARD_DEVIATION 1.5
Sex: Female, Male
Female
7 Participants6 Participants13 Participants
Sex: Female, Male
Male
4 Participants4 Participants8 Participants
Weight66.1 kg
STANDARD_DEVIATION 18.3
76.1 kg
STANDARD_DEVIATION 18.1
71.1 kg
STANDARD_DEVIATION 18.2

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 110 / 10
other
Total, other adverse events
7 / 118 / 10
serious
Total, serious adverse events
0 / 110 / 10

Outcome results

Primary

Color Trails Test (CTT)

Measure sustained attention. The CTT uses numbered coloured circles and universal sign language symbols. The circles are printed with vivid pink or yellow backgrounds that are perceptible to colourblind individuals. For the Colour Trails 1 trial, the respondent uses a pencil to rapidly connect circles numbered 1 through 25 in sequence. Less time indicates better performance (min=10, max= 240).

Time frame: 5-8 minutes

Population: Color Trails Test 1. Execution time

ArmMeasureValue (MEAN)Dispersion
4-aminopyridineColor Trails Test (CTT)68.91 units on a scale (seconds)Standard Deviation 40.7
PlaceboColor Trails Test (CTT)67.3 units on a scale (seconds)Standard Deviation 37.4
p-value: 0.92t-test, 1 sided
Primary

Five Digit Test (FDT). Processing Speed

Processing speed information (which includes reading, count, and alternation speed). Cards with a different number of stimuli are shown to the patient, who has to read, count, and respond to a change of instructions (alternation). Reading speed (min 12, max 31+ seconds), counting speed (min 14, max 28+ seconds), and alternation speed (min 26, max 56+ seconds) are recorded. Less speed corresponds to a better outcome.

Time frame: 8-10 min

ArmMeasureGroupValue (MEAN)Dispersion
4-aminopyridineFive Digit Test (FDT). Processing SpeedReading speed28 secondsStandard Deviation 9
4-aminopyridineFive Digit Test (FDT). Processing SpeedCount speed30.5 secondsStandard Deviation 9.2
4-aminopyridineFive Digit Test (FDT). Processing SpeedAlternation speed60.3 secondsStandard Deviation 25.7
PlaceboFive Digit Test (FDT). Processing SpeedCount speed34.2 secondsStandard Deviation 12
PlaceboFive Digit Test (FDT). Processing SpeedReading speed29.6 secondsStandard Deviation 4.2
PlaceboFive Digit Test (FDT). Processing SpeedAlternation speed58.8 secondsStandard Deviation 17.7
Comparison: Reading speedp-value: 0.64t-test, 1 sided
Comparison: Count speedp-value: 0.43t-test, 1 sided
Comparison: Alternationp-value: 0.9t-test, 1 sided
Primary

Integrated Program of Neuropsychological Exploration Test Barcelona

Integrated Program of Neuropsychological Exploration Test Barcelona: Digit Span Forward (DSF), (attention spam and improved scoring metrics significantly enhance the precision of DSF assessments of short-term verbal memory). Digit sequences are presented beginning with a length of two digits and two trials are presented at each increasing list length. Max score 8 and min score 0 digits. Higher scores indicate a better cognitive performance.

Time frame: 7-10 min

Population: Attention spam.

ArmMeasureValue (MEAN)Dispersion
4-aminopyridineIntegrated Program of Neuropsychological Exploration Test Barcelona6.1 correct numbers recalledStandard Deviation 1.5
PlaceboIntegrated Program of Neuropsychological Exploration Test Barcelona5 correct numbers recalledStandard Deviation 0.8
p-value: 0.001t-test, 1 sided
Primary

Rey-Osterrieth Complex Figure Test (ROCF)

The purpose of this test is to assess visual-spatial constructional ability and visual memory. The time required to copy the drawing is recorded. Less time indicates a better performance and more time indicates a worse outcome (min score 60 and max score 300 seconds).

Time frame: 10-15 minutes

ArmMeasureValue (MEAN)Dispersion
4-aminopyridineRey-Osterrieth Complex Figure Test (ROCF)208.6 units on a scale (seconds)Standard Deviation 121.2
PlaceboRey-Osterrieth Complex Figure Test (ROCF)231.2 units on a scale (seconds)Standard Deviation 114.8
p-value: 0.016t-test, 1 sided
Primary

The Brief Repeatable Battery of Rao

Neuropsychological tests to assess: verbal fluency. Participants have to say as many words as possible from a category in a given time 60 Sec (F, A, S) Max score 72 and min score 19 words. Higher scores indicate a better cognitive performance.

Time frame: 10-15 minutes

Population: Word List Generation (3 trials/60 sec)

ArmMeasureValue (MEAN)Dispersion
4-aminopyridineThe Brief Repeatable Battery of Rao42.09 Correct wordsStandard Deviation 14.5
PlaceboThe Brief Repeatable Battery of Rao35.5 Correct wordsStandard Deviation 6.6
p-value: 0.028t-test, 1 sided
Primary

Tower Of London (TOL). Execution Time and Problem-solving Time

Measures higher-order problem-solving ability. The information it provides is not only useful when assessing frontal lobe damage, but also when evaluating attention disorders and executive functioning difficulties. The administrator arranges red, green, and blue beads on a peg board to match the configuration in the diagram. The patient is asked to replicate the configuration on a second peg board. Scores are calculated for Total Execution Time (since the patient performs the first move until he ends the test), Total Problem-Solving Time (the sum of planning and execution times). Total execution time higher scores indicate a worse outcome (min= 0-78, max=564+ seconds), Total problem-solving time higher scores indicate a worse outcome (min= 0-56, max=500+ seconds).

Time frame: 25-30 minutes

ArmMeasureGroupValue (MEAN)Dispersion
4-aminopyridineTower Of London (TOL). Execution Time and Problem-solving TimeTotal execution time296.2 secondsStandard Deviation 109.3
4-aminopyridineTower Of London (TOL). Execution Time and Problem-solving TimeTotal problem-solving time363.3 secondsStandard Deviation 130
PlaceboTower Of London (TOL). Execution Time and Problem-solving TimeTotal execution time367.9 secondsStandard Deviation 265.4
PlaceboTower Of London (TOL). Execution Time and Problem-solving TimeTotal problem-solving time426.8 secondsStandard Deviation 278.9
Comparison: Execution timep-value: 0.001t-test, 1 sided
Comparison: Problem-solving timep-value: 0.001t-test, 1 sided
Primary

Tower Of London (TOL). Total Moves and Total Correct Moves

Measures higher order problem-solving ability. The information it provides is not only useful when assessing frontal lobe damage, but also when evaluating attention disorders and executive functioning difficulties. The administrator arranges red, green, and blue beads on a peg board to match the configuration in the diagram. The patient is asked to replicate the configuration on a second peg board. Scores are calculated for Total Correct Moves and Total Moves. Total moves: higher scores indicate a worse cognitive performance (min= 0, max=58+); Total correct higher scores indicate a better cognitive performance (min=0, max=10).

Time frame: 25-30 minutes

ArmMeasureGroupValue (MEAN)Dispersion
4-aminopyridineTower Of London (TOL). Total Moves and Total Correct MovesTotal moves42.7 score on a scaleStandard Deviation 19.7
4-aminopyridineTower Of London (TOL). Total Moves and Total Correct MovesCorrect moves4 score on a scaleStandard Deviation 2.7
PlaceboTower Of London (TOL). Total Moves and Total Correct MovesTotal moves50.8 score on a scaleStandard Deviation 23.9
PlaceboTower Of London (TOL). Total Moves and Total Correct MovesCorrect moves3 score on a scaleStandard Deviation 1.9
Comparison: Total movesp-value: 0.017t-test, 1 sided
Comparison: Correct movesp-value: 0.01t-test, 1 sided
Primary

Wisconsin Card Sorting Test (WCST)

Is used primarily to assess perseveration and abstract thinking, allows the clinician to assess the following 'frontal' lobe functions: strategic planning, organised searching, utilising environmental feedback to shift cognitive sets, directing behaviour toward achieving a goal. WCST measures abstract reasoning and ability to alter problem solving strategies. Patients are given 128 response cards and 4 stimulus cards and asked to match each stimulus card to 1 pile of response cards. The patient is not told how to match the cards, only right or wrong to each placement. The examiner may change matching rules during the test. Perseveration errors occur when subject repeats the same error no matter how many times they are told the placement is wrong. Higher scores indicate a worse cognitive performance (min=0-3, max=58-126)

Time frame: 10-15 minutes

ArmMeasureValue (MEAN)Dispersion
4-aminopyridineWisconsin Card Sorting Test (WCST)19.8 score on a scaleStandard Deviation 35.6
PlaceboWisconsin Card Sorting Test (WCST)22.8 score on a scaleStandard Deviation 32.2
p-value: 0.83t-test, 1 sided
Secondary

Fatigue

The Fatigue Severity Scale (FSS) is one of the most frequently used inventories for measuring fatigue in people with chronic illnesses. The FSS questionnaire is comprised of nine statements inquiring about the examinee's sleep habits over the preceding week. Ratings are on a 7-point Likert scale, where higher scores indicate how strongly the patient agrees with the nine statements.Scale. Scoring using a bimodal response system or a Likert score with weights assigned to each response choice. Likert or bimodal rating scales with 4 response options. For the Likert Scale: better than usual= 0, no more than usual= 1, worse than usual= 2, much worse than usual= 3. For the bimodal scale: better than usual= 0, no more than usual= 0, worse than usual= 1, much worse than usual= 1. Sum all items for a total score. Score range. Range is 0 -11 for bimodal response format. Interpretation of scores. Higher score indicates more fatigue. Self report scale

Time frame: 10 minutes

ArmMeasureValue (MEAN)Dispersion
4-aminopyridineFatigue4.3 score on a scaleStandard Deviation 1.4
PlaceboFatigue3.3 score on a scaleStandard Deviation 1.8
Secondary

Improved Physical Capacity

The Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time. It is widely used in clinical trials and in the assessment of people with MS. The EDSS scale ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability. Scoring is based on an examination by a neurologist. The first levels 1.0 to 4.5 refers to people with a high degree of ambulatory ability and the subsequent levels 5.0 to 9.5 refers to the loss of ambulatory ability. It also provides eight subscale measurements called Functional System (FS) scores. The levels of function within each category refer to the eight FS affected by MS: The FS are scored on a scale of 0 (low level of problems) to 5 (high level of problems) to best reflect the level of disability observed clinically.

Time frame: 15-20 minutes

ArmMeasureValue (MEAN)Dispersion
4-aminopyridineImproved Physical Capacity4.6 score on a scaleStandard Deviation 1.55
PlaceboImproved Physical Capacity4.04 score on a scaleStandard Deviation 1.27
Secondary

Number of Participants With Abnormal Studies

Safety surveillance will be done every two weeks from the beginning of the study, intentionally searching for adverse events (AE). EEG (Diffuse or focal cerebral dysfunction through demonstration of background slowing or presence of epileptiform activity assessed by a neurophysiologist) and laboratory tests (Presence of values higher of the normal value established by local laboratory and related to the administration of treatments), blood and urine samples: creatinine, blood urea nitrogen, total cholesterol, triglycerides, total direct, and indirect bilirubin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, creatinine kinase, lactic acid dehydrogenase, amylase and lipase. A complete blood cell count with differentials and a routine urinalysis and urine culture also obtained at each visit, will be done before the patients take 40, 50 and 60 mg/day. The number of participants with abnormal studies were reported.

Time frame: 22 weeks

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
4-aminopyridineNumber of Participants With Abnormal StudiesNumber of participants with abnormal lab results1 Participants
4-aminopyridineNumber of Participants With Abnormal StudiesNumber of participants with abnormal EEG0 Participants
PlaceboNumber of Participants With Abnormal StudiesNumber of participants with abnormal lab results0 Participants
PlaceboNumber of Participants With Abnormal StudiesNumber of participants with abnormal EEG0 Participants
Secondary

Walk

Timed 25 Foot Walk Test (T25-FW). The T25-FW is a quantitative mobility and leg function performance test based on a timed 25-walk. The patient is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time is calculated from the initiation of the instruction to start and ends when the patient has reached the 25-foot mark. The task is immediately administered again by having the patient walk back the same distance. Patients may use assistive devices when doing this task. TIME LIMIT PER TRIAL (2) 3 minutes (180 seconds) per trial.

Time frame: 5-10 minutes

ArmMeasureValue (MEAN)Dispersion
4-aminopyridineWalk15.2 secondsStandard Deviation 13.3
PlaceboWalk10.4 secondsStandard Deviation 5.7

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026